Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

Apixaban was the third nonvitamin K antagonist oral anticoagulants introduced to clinical practice, and increasing real-world studies have been published. Our aim was to summarize current evidence ...

Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine , 2011; 110827230022006 DOI: 10.1056/NEJMoa1107039 Cite This Page : ...

Apixaban dose was adjusted to 2.5 mg twice daily for subjects with any two of the following: age ≥80 years, body weight ≤60 kg, and serum creatinine ≥1.5 mg/dl. Outcomes and treatment effect were ...

Apixaban is an oral anticoagulant that inhibits factor Xa. It is one of a clutch of new oral agents competing with warfarin as a first line treatment for people with atrial fibrillation. Drug trials ...

Apixaban was also more clinically effective than dabigatran etexilate and enoxaparin. Both apixaban and rivaroxaban dominated dabigatran etexilate and enoxaparin in the analyses for total knee ...

Regarding kidney function, apixaban reduced the risk of stroke/SE by 37% in those with an eGFR of <30 ml/min/1.73 m 2 (aHR: 0.63; 95% CI: 0.40–0.98; p = 0.04). Conclusions: Compared to warfarin, ...

The RENAL-AF trial (Renal Hemodialysis Patients Allocated Apixaban Versus Warfarin in Atrial Fibrillation) was a prospective, randomized, open-label, blinded-outcome evaluation (PROBE) of apixaban ...

Apixaban was associated with a lower risk of GIB for patients with chronic kidney disease or over 80 years old compared to dabigatran, edoxaban, or rivaroxaban. Evidence Rating Level: 1. 1. In this ...

Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation. You are here: Home NICE Guidance Conditions and ...